|
Nanospectra Biosciences Closes on $1.7 million in Series A Preferred
Stock
First Closing
Devoted to Clinical Trial of AuroLase Cancer Therapy
November 2, 2006
Nanospectra Biosciences Receives $1,250,000 Texas ETF Award
Award
Funds AuroLase Cancer Therapy Clinical Development
September 27, 2006
Nanospectra Biosciences Receives Additional $500,000 NSF Cancer
Grant
SBIR
Phase II Grant Funds Continued Development of Cancer Therapy
February 14, 2006
Nanospectra Biosciences Receives $392,000 NSF Cancer Grant
STTR
Phase II Grant Funds Continued Development of Cancer Therapy
February 17, 2005
Nanospectra
Biosciences Receives $750,000 Air Force Grant
STTR
Phase II Grant Funds Development of Chemical and Biosensing Platform
January 5, 2005
Nanospectra
Biosciences Receives $428,000 NIH Grant
Funds
Development of Platform for Detection of Alzheimer's Related Proteins
September 29, 2004
Nanospectra
Biosciences Receives $2 Million NIST ATP Award
Funds
Development of Technique for Seamless Detection and Treatment of
Cancer
September 28, 2004
Nanospectra and M. D. Anderson Sign Technology Option Agreement
M.
D. Anderson Acquires Minority Equity Position in Nanospectra
September 24, 2002
|
